Evidence map›Paper›PMID 42529639›Full record

ArticleChemical & biomedical imaging2026

[

You Zhang, Qianyun Wu, Shuxian An, Dongsheng Xu, Wenzhi Jia, Zhoumi Hu, Cheng Wang, Gang Huang, Jin Zhang, Jianjun Liu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical & biomedical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

You ZhangDepartment of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai 200127, China.
Qianyun WuDepartment of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai 200127, China.
Shuxian AnDepartment of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai 200127, China.
Dongsheng XuDepartment of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai 200127, China.
Wenzhi JiaDepartment of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai 200127, China.
Zhoumi HuDepartment of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai 200127, China.
Cheng WangDepartment of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai 200127, China.
Gang HuangDepartment of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai 200127, China.
Jin ZhangDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai 200127, China.
Jianjun LiuDepartment of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai 200127, China.
Weijun WeiDepartment of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai 200127, China.ORCID https://orcid.org/0000-0003-3190-2480

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precise diagnosis of primary and metastatic clear cell renal cell carcinoma (ccRCC) is an unmet clinical challenge. CD70 is a biomarker for ccRCC, with high, consistent expression in both primary and metastatic diseases. Devising immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging tracers targeting CD70 will enable noninvasive, accurate diagnosis of ccRCC. By immunizing alpacas with the recombinant human CD70 protein, we obtained a single-domain antibody (sdAb), R8B4, with an affinity of 9.583 nM. First, by harnessing

Indexed as

ccRCCCD70clinical translationimmunoPET/CTsingle-domain antibody

Identifiers

PMID42529639
PMCPMC13417530

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.